Clopidogrel Taw Pharma (previously Clopidogrel Mylan)

Clopidogrel Taw Pharma is a medicine used to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) in adults who have: - recently had a myocardial infarction (heart attack). Clopidogrel Taw Pharma can be started between a few days and 35 days after the attack; - recently had an ischaemic stroke (stroke caused by insufficient blood supply to part of the brain). Clopidogrel Taw Pharma can be started between seven days and six months after the stroke; - peripheral arterial disease (problems with blood flow in the arteries); - a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots). Acute coronary syndrome is a group of heart problems that include unstable angina (a severe type of chest pain) and certain types of heart attack. Some of these patients may have had a stent (a short tube) inserted into an artery to prevent it from closing up. Clopidogrel Taw Pharma is also used to prevent problems caused by blood clots in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin. It is used in patients who have at least one risk factor for events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding. Clopidogrel Taw Pharma contains the active substance clopidogrel and is a ‘generic medicine’. This means that Clopidogrel Taw Pharma contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Plavix. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf).